Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Erenumab prevents the occurrence of migraine attacks and not just migraine days : Post-hoc analyses of a phase III study. / Diener, Hans Christoph; Ashina, Messoud; Ritter, Shannon; Paiva Da Silva Lima, Gabriel; Rasmussen, Soeren; Zielman, Ronald; Tfelt-Hansen, Peer.
I: Cephalalgia, Bind 41, Nr. 11-12, 2021, s. 1262-1267.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Erenumab prevents the occurrence of migraine attacks and not just migraine days
T2 - Post-hoc analyses of a phase III study
AU - Diener, Hans Christoph
AU - Ashina, Messoud
AU - Ritter, Shannon
AU - Paiva Da Silva Lima, Gabriel
AU - Rasmussen, Soeren
AU - Zielman, Ronald
AU - Tfelt-Hansen, Peer
N1 - Publisher Copyright: © International Headache Society 2021.
PY - 2021
Y1 - 2021
N2 - Background: This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them. Methods: We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed. Results: Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks. Conclusion: These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks. Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740)
AB - Background: This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them. Methods: We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed. Results: Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks. Conclusion: These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks. Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740)
KW - episodic migraines
KW - erenumab
KW - monthly migraine attacks
KW - monthly migraine days
KW - STRIVE study
U2 - 10.1177/03331024211010308
DO - 10.1177/03331024211010308
M3 - Journal article
C2 - 33939497
AN - SCOPUS:85105733309
VL - 41
SP - 1262
EP - 1267
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 11-12
ER -
ID: 303676984